부인 악성종양 환자의 혈청면역억제산성 단백 ( IAP ) 측정의 의의 = Significance of Immunosuppressive Acidic Protein Assay in Patients with Gynecologic Cancer

다국어 초록 (Multilingual Abstract)

To elucidate the significance of the immunosuppressive acidic protein(IAP) assay as a diagnostic marker and to know the relationship between the IAP level and the clinical status in patients with various gynecologic cancer, we measured the IAP level in 7 cervical dysplasis patients, 10 carcinoma in situ patients, 73 cervical cancer patients, 5 endometrial cancer patients, 11 benign ovarian tumor patients, 10 ovarian cancer patients and 47 healtyh females. 1. The mean value of serum IAP in 47 healthy females was 308.9 93.3 g/ml and the positive rate(more than 500 g/ml) was 2.1%. 2. The mean value of IAP and the positive rate were not significantly higher in patients with cervical dysplasia(351.4 114.2 g/ml;14.3%) and CIS(347.5 85.6 g/ml;10%) than in normal control, but were significantly higher in patients with cervical cancer(477.2 223.4 g/ml;40.6%), recurrent cervical cancer(678.8 242.2 g/ml;100%), ovarian cancer(750.5 103.7 g/ml;90.0%), and benign ovarian tumor(409.5 5 g/ml;18.2%). The mean value of IAP in patients with ovarian cancer was statistically significantly higher than in patients with benign ovarian tumors. 3. The mean value of IAP and the positive rate showed a tendency to increase with advancing stage of cervical cancer(from 25.8% in stage Ⅰ to 66.7% in stage Ⅳ and 100% in recurrent cases.). The positive rate in each stage was similar to that of CEA. The combination of these two assays increase the detection rate of cervical cancer and may be useful in monitoring the recurrence of cervical cancer. 4. The mean value of IAP and the positive rate increased with advancing stage of ovarian cancer. The positive rate of IAP(90%) was significantly higher than that of CEA(40%), especially in early stage(66.7% 0%). We concluded that serial IAP determination seemed to provide a useful follow-up marker in patients with gynecologic cancer, especially in whom CEA was low in value. Especially in ovarian cancer, serum IAP assays may be useful for diagnostic purpose and for monitoring the result of the treatme